BioVenture VoiCes with Chris Garabedian

Josh Resnick describes his career path, which includes working on the venture side of both private funds and pharma (Merck). He explains the different investment strategies of RA Capital, and talks about how the firm's Raven company building incubator fits in. Plus, his thoughts on venture investing in the current environment.

Steve Tregay describes his career path, including how early roles at Array BioPharma and Novartis led him to found Forma Therapeutics. He describes the founding and growth of LabCentral, for which he is still the chairman today, and how getting a look at entrepreneurs at such an early stage naturally led to the investment work that he and his partners do at Mission BioCapital.

Joe Jimenez, former Novartis CEO and now co-founder of Aditum Bio focused on translational medicine. He traces his path from consumer brands to pharma leadership. He outlines Aditum’s clinic-directed, shared-services model for IND-to-Phase II programs. He explains the firm’s three investment criteria and why they favor predictable biology over early preclinical oncology.

Shahram describes his upbringing as a refugee from Iran, his early career in law and banking, and how his initial experience in the tech industry has benefitted his eye towards life sciences. He recalls founding Civilization Ventures with an initial $1M fund, and talks about what it has quickly grown into today, Plus, his take on AI and the current state of tech bio.

A General Partner at Flagship Pioneering, Avak describes his upbringing and studies in the Middle East and Montreal, Canada, working in industry at Helicos, and co-founding companies at Flagship since 2011. He discusses Flagship's unique platform of company building and innovation.

A Partner at Pillar VC, Tony describes his start at MIT, founding the MIT BioMakerspace, his work at Petri, being an early supporter of Nucleate, and his philosophy of not being overly influenced by what is in vogue today.

The Co-Founder and Operating Chairman of Curie.Bio, and serial entrepreneur, shares experiences from his early life, CombinatoRx, Foundation Medicine, Third Rock, EQRx and more.

He describes his career path and learnings from the tech industry, co-founding Adimab, the work that Alloy and 82VS do to support and invest in scientist-entrepreneurs, and why he believes smaller organizations are best suited for discovery work and other early stage innovation.

Julie Grant, a general partner at Canaan Partners with a robust background in healthcare investments from Goldman Sachs and Genentech, shares her dynamic career journey. She highlights the importance of industry connections and reflects on her time at Genentech, emphasizing the complexities of biotech commercialization. Julie discusses Canaan's bold investment strategies in new medicine categories and the significance of innovation in drug development, advocating for contrarian thinking to drive effective therapies forward. Her insights offer a fascinating look into the evolving landscape of healthcare investments.

MPM's founder and managing partner discusses the firm's 30+ years of investing in life sciences, including the philosophy of placing entrepreneur partners at companies from the start, and teaming up with research institutions and investment collaborators. Plus, the keys making it through a down cycle like the industry has been in over recent years.